Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung

被引：0

作者：

Oxnard, Geoffrey R. ^{[1
]}

Thress, Kenneth ^{[2
]}

Paweletz, Cloud ^{[1
]}

Stetson, Daniel ^{[2
]}

Dougherty, Brian ^{[2
]}

Lai, Zhongwu ^{[2
]}

Markovets, Aleksandra ^{[2
]}

Felip, Enriqueta ^{[3
]}

Vivancos, Ana ^{[4
]}

Kuang, Yanan ^{[1
]}

Sholl, Lynette ^{[5
]}

Redig, Amanda J. ^{[1
]}

Cantarini, Mireille ^{[6
]}

Barrett, J. Carl ^{[2
]}

Pillai, Rathi N. ^{[7
]}

Cho, Byoung Chul ^{[8
]}

Lacroix, Ludovic ^{[9
]}

Planchard, David ^{[9
]}

Soria, Jean Charles ^{[9
]}

Jaenne, Pasi A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Astrazeneca, Waltham, MA USA

[3] Vall DHebron Univ Hosp, Barcelona, Spain

[4] Vall DHebron Inst Oncol, Barcelona, Spain

[5] Brigham & Womens Hosp, Boston, MA 02115 USA

[6] Astrazeneca, Macclesfield, Cheshire, England

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Yonsei Canc Ctr, Seoul, South Korea

[9] Gustave Roussy, Villejuif, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

AZD9291; EGFR-TKI; T790M;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL17.07

引用

页码：S207 / S207

页数：1

共 50 条

[21] Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma
Rood, Johannes J. M.
van Bussel, Mark T. J.
Schellens, Jan H. M.
Beijnen, Jos H.
Sparidans, Rolf W.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1031 : 80 - 85
[22] The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
Remon, Jordi
Menis, Jessica
Hasan, Baktiar
Peric, Aleksandra
De Maio, Eleonora
Novello, Silvia
Reck, Martin
Berghmans, Thierry
Wasag, Bartosz
Besse, Benjamin
Dziadziuszko, Rafal
CLINICAL LUNG CANCER, 2017, 18 (05) : 583 - 588
[23] EGFR T790M mutation testing within a phase I study with AZD9291.
Dearden, Simon Patrick
Brown, Helen
Cole, Rebecca
Jenkins, Suzanne
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA
Kim, Y.
Park, C.
Oh, I.
Lim, J.
Choi, Y.
Cho, H.
Ahn, S.
Song, S.
Yun, J. S.
Na, K.
Kim, S.
Park, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2135 - S2136
[25] AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study
Karachaliou, Niki
Morales-Espinosa, Daniela
Molina Vila, Miguel Angel
Garde, Javier
Baron, Francisco
Cobo, Manuel
Lopez-Vivanco, Guillermo
Majem, Margarita
Miguel Sanchez, Jose
Viteri, Santiago
Mayo, Clara
Garcia, Margarida
Rosell, Rafael
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1074 - S1075
[26] Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
Saad, Nibal
Poudel, Aarati
Basnet, Alina
Gajra, Ajeet
ONCOTARGETS AND THERAPY, 2017, 10 : 1757 - 1765
[27] Acquired T790M resistance do afatinib in EGFR mutated lung adenocarcinoma
Miyazaki, Kunihiko
Sato, Shinya
Kodama, Takahide
Satoh, Hiroaki
Hizawa, Nobuyuki
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (04): : 317 - 318
[28] AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells
Ku, Bo Mi
Bae, Yeon-Hee
Koh, Jiae
Sun, Jong-Mu
Lee, Se-hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 407 - 415
[29] Diverse EGFR mutations explain AZD9291 resistance
Nature Reviews Clinical Oncology, 2015, 12 : 438 - 438
[30] AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells
Bo Mi Ku
Yeon-Hee Bae
Jiae Koh
Jong-Mu Sun
Se-hoon Lee
Jin Seok Ahn
Keunchil Park
Myung-Ju Ahn
Investigational New Drugs, 2016, 34 : 407 - 415

← 1 2 3 4 5 →